---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116493"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:47:15.252059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025

## Summary
- PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.
- China Phase 3 met primary endpoint: 40.5% conversion vs 15.9% placebo within 30 min (HR=3.00, p<0.001).
- Phase 3 trial in AFib-RVR expected to start H1 2025 with repeat-dose 70 mg regimen.
- Cash, equivalents and short-term investments $76.4M at Sep 30, 2024, up from $66.0M at Dec 31, 2023.
- Net loss narrowed to $9.4M in Q3 2024 vs $15.1M in Q3 2023; R&D expense $4.0M vs $6.7M.

## SEC filing metadata
- accession: 0001104659-24-116493
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/0001104659-24-116493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116493
- JSON: https://secwatch.observer/filing/0001104659-24-116493.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.